Barron's Logo

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/sarepta-stock-gene-therapy-duchenne-muscular-dystrophy-fda-cc01c057

FDA Approves Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy

By
Josh Nathan-Kazis
  • Order Reprints
  • Print Article

The Food and Drug Administration on Thursday approved Sarepta Therapeutics ’ one-time gene therapy treatment for children with Duchenne muscular dystrophy, despite unanswered questions about the drug’s clinical benefit.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.